SEI Investments’s Spero Therapeutics SPRO Stock Holding History

SEI Investments’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-132,010	Closed	-$308K	–	3325
2025 Q4	$308K	Buy	+132,010	New	+$307K	﹤0.01%	2728

Other funds holding SPRO

GSK plc London $599M AUM

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SEI Investments's SPRO Position: Q1 2026 in Review

SEI Investments sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 132,010 shares — an estimated $308K sold.

SEI Investments first reported a position in SPRO in Q4 2025 and held it in 1 quarter. The position peaked at $308K in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

SEI Investments reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
SEI Investments sold 132,010 Spero Therapeutics shares in Q1 2026, an estimated $308K.
SEI Investments first reported a position in Spero Therapeutics in Q4 2025 and held it in 1 quarter.
SEI Investments's Spero Therapeutics position peaked at $308K in Q4 2025.
50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.